Transaction overview
Adam S. Grossman, President and CEO of ADMA Biologics, Inc. (NASDAQ: ADMA), executed a sale of 21,000 shares of the company’s common stock on March 16, 2026. The shares were sold at $15.16 each, producing proceeds of $318,360. On that same date Grossman also exercised stock options to purchase 15,000 shares at an exercise price of $5.40 per share, for a cash outlay of $81,000.
Current market context and ownership
ADMA’s common shares are trading at $16.15 at the time of reporting, giving the company a market capitalization of $3.85 billion. Following the March 16 transactions, Grossman’s direct ownership stands at 2,112,777 shares. In addition to his direct stake, Grossman holds an indirect interest of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC.
Third-party valuation and profitability note
An InvestingPro analysis included in the company’s public commentary indicates that ADMA appears undervalued at current price levels and has been profitable over the trailing twelve months. The InvestingPro platform is cited as providing Fair Value estimates and more than 10 additional ProTips intended to assist investors seeking deeper analysis.
Recent financial performance
Separately, ADMA Biologics reported strong fourth-quarter 2025 financial results, with total revenue for the quarter of $139.2 million, representing an 18% increase year over year. Adjusted net income for the quarter rose by 57% to $52.6 million. The company’s quarterly report is described as reflecting robust performance, and was met with cautious optimism from investors. The earnings release did not prompt any notable analyst upgrades or downgrades, signaling a steady consensus among analysts following the results.
What the filings show
The disclosure in the securities filings documents both the open-market sale of shares and the option exercise on March 16, 2026, and records Grossman’s resulting direct and indirect holdings. The combination of a sale and a same-day option exercise is reflected in the reported transaction amounts and post-transaction ownership figures.
Conclusion
Grossman’s activity on March 16 included both a sale and an exercise of options, leaving him with sizeable direct and indirect stakes in ADMA Biologics. These ownership figures are reported alongside recent quarterly results that show revenue and adjusted net income growth and a third-party view citing the stock as potentially undervalued. The company’s market capitalization is reported at $3.85 billion with shares trading at $16.15.
Note: The article reflects the transactions, ownership details, market data, third-party analysis, and quarterly results as reported in company filings and public commentary.